0001558370-24-011806 | 10-Q | XBRL Viewer

Leases	6 Months Ended
Jun. 30, 2024
Leases
Leases	3. Leases The Company is party to one operating lease for office and laboratory space. The Company’s finance leases are immaterial both individually and in the aggregate. The Company has elected to apply the short-term lease exception to all leases of one year or less. Rent expense for each of the three months ended June 30, 2024 and 2023 was $19,997. Rent expense for each of the six months ended June 30, 2024 and 2023 was $39,995, which is included in operating expenses. The Company has an annual operating lease for office and laboratory space in Doylestown, Pennsylvania which was renewed for 2024 and is currently set to expire on December 31, 2024. Rent expense under this lease is $110,000 annually and the Company has applied the short-term exception to this lease. The Company has no lease obligations beyond 2024.

Leases

6 Months Ended

Jun. 30, 2024

3. Leases

The Company is party to one operating lease for office and laboratory space. The Company’s finance leases are immaterial both individually and in the aggregate. The Company has elected to apply the short-term lease exception to all leases of one year or less. Rent expense for each of the three months ended June 30, 2024 and 2023 was $19,997. Rent expense for each of the six months ended June 30, 2024 and 2023 was $39,995, which is included in operating expenses.

The Company has an annual operating lease for office and laboratory space in Doylestown, Pennsylvania which was renewed for 2024 and is currently set to expire on December 31, 2024. Rent expense under this lease is $110,000 annually and the Company has applied the short-term exception to this lease. The Company has no lease obligations beyond 2024.

Accrued expenses (Tables)

6 Months Ended

Jun. 30, 2024

Accrued expenses

Schedule of accrued expenses


	June 30,		December 31,
	2024		2023
Professional fees	$	209,372	$	138,601
Compensation, severance and benefits		582,437		1,016,960
Research and development		1,240,751		856,575
Other		46,603		174,126
Total accrued expenses	$	2,079,163	$	2,186,262

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 28,694,694	$ 21,606,820
Prepaid expenses and other current assets	865,092	914,275
Total current assets	29,559,786	22,521,095
Property and equipment, net	92,379	88,362
Restricted cash	41,260	40,717
Other noncurrent assets	271,162
Total assets	29,964,587	22,650,174
Current liabilities:
Accounts payable	964,327	1,670,369
Accrued expenses	2,079,163	2,186,262
Deferred grant revenue	50,739	528,974
Total current liabilities	3,094,229	4,385,605
Commitments and contingencies (Note 7)
Stockholders' equity:
Common stock, $0.001 par value, 400,000,000 shares authorized, 5,430,215 and 3,736,673 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	5,430	3,736
Additional paid-in capital	350,545,473	335,644,204
Accumulated other comprehensive loss	(10,628,304)	(10,611,273)
Accumulated deficit	(314,363,304)	(308,083,161)
Total stockholders' equity	25,559,295	16,953,506
Total liabilities and stockholders' equity	29,964,587	22,650,174
Series A Convertible Preferred Stock
Convertible preferred stock:
Series A convertible preferred stock, $0.001 par value, 40,000,000 shares authorized; 56,227 shares issued and outstanding at June 30, 2024 and December 31, 2023	$ 1,311,063	$ 1,311,063

Summary of significant accounting policies - Restricted cash (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Summary of significant accounting policies
Restricted cash	$ 41,260	$ 40,180

Accrued expenses

6 Months Ended

Jun. 30, 2024

Accrued expenses

Accrued expenses

4. Accrued expenses

Accrued expenses consist of the following:


	June 30,		December 31,
	2024		2023
Professional fees	$	209,372	$	138,601
Compensation, severance and benefits		582,437		1,016,960
Research and development		1,240,751		856,575
Other		46,603		174,126
Total accrued expenses	$	2,079,163	$	2,186,262

Leases - Summary (Details)	3 Months Ended		6 Months Ended
Leases - Summary (Details)	Jun. 30, 2024 USD ($) lease	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) lease	Jun. 30, 2023 USD ($)
Leases
Number of operating leases \| lease	1		1
Rent expense	$ 19,997	$ 19,997	$ 39,995	$ 39,995
Annual base rent			110,000
Lease obligations after current year			$ 0

Nature of business and basis of presentation

6 Months Ended

Jun. 30, 2024

Nature of business and basis of presentation

Nature of business and basis of presentation

1. Nature of business and basis of presentation

Nature of business—Aprea Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company began principal operations in 2006 and is headquartered in Doylestown, Pennsylvania. Prior to the acquisition of Atrin Pharmaceuticals Inc. (“Atrin”) in May 2022, the Company was engaged in the clinical development of cancer therapeutics that reactivate the mutant p53 tumor suppressor protein. In December 2020, the Company announced that its pivotal Phase 3 myelodysplastic syndromes trial failed to meet its predefined primary endpoint of complete remission (CR) rate. Given these results, FDA feedback and the costs of continuing the APR-246 development program, the Company shifted focus of its activities to the assets acquired in the May 2022 acquisition of Atrin. The Company’s two clinical programs are a novel oral macrocyclic ATR inhibitor, ATRN-119, and our next-generation oral inhibitor of the WEE1 kinase, APR-1051. Both programs are the cornerstones of our pipeline of synthetic lethality-based cancer therapeutics and were internally discovered, developed, and evaluated by our dedicated team of chemists, scientists, and clinicians.

Basis of presentation and management plans—The accompanying financial statements are prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

Since its inception, the Company has devoted substantially all of its efforts to business planning, clinical operations, research and development, recruiting management, technical staff, raising capital and has financed its operations through the issuance of convertible preferred stock and common stock.

The Company is subject to risks common to companies in the biopharmaceutical industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be maintained, that any therapeutic products developed will obtain required regulatory approval or that any approved or consumer products will be commercially viable. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales.

The Company believes that the June 30, 2024 cash balance of approximately $28.7 million will be sufficient to fund the Company’s operations into the fourth quarter of 2025. In the event that additional funds are not available thereafter, management would expect to significantly reduce expenditures to conserve cash, which would involve scaling back or curtailing new development activity.

Income taxes

6 Months Ended

Jun. 30, 2024

Income taxes

Income taxes

6. Income Taxes

The Company has no income tax expense due to operating losses incurred for the three and six months ended June 30, 2024 and 2023. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period.

Realization of the future tax benefits is dependent on may factors, including the Company’s ability to generate taxable income within the net operating loss carryforward period. Under the provisions of the U.S. Internal Revenue Code and Sweden tax law, certain substantial changes in the Company’s ownership, including a sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of net operating loss carryforwards that could be used annually to offset future taxable income. For U.S. and Swedish income tax purposes, the Company has not completed a study to assess whether a change of control has occurred or whether there have been changes of control since the Company’s formation due to the complexity and cost associated with such study and because there could be additional changes of control in the future. As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company’s ability to utilize U.S. or Swedish net operating losses or other tax attribute carryforwards in the future. For Swedish income tax purposes, the Company’s net operating losses may be subject to limitations in accordance with the country’s group contribution restriction laws.

The Company files tax returns in Sweden, the United States, Massachusetts and Pennsylvania. Income tax returns prior to 2020 in the United States and Massachusetts are no longer subject to examination and income tax returns prior to 2017 are no longer subject to examination in Sweden. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years.

As tax law is complex and often subject to varied interpretations, it is uncertain whether some of the Company’s tax positions will be sustained upon examination. Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in the Company’s financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. Substantially all of these unrecognized tax benefits, if recognized, would benefit the Company’s effective income tax rate.

As of June 30, 2024 and December 31, 2023, the Company had approximately $0.1 million of liabilities related to uncertain tax positions. As the Company’s uncertain tax positions can be offset by available net operating losses, the Company did not recognize interest and penalties for 2024 and 2023.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Pay vs Performance Disclosure - USD ($)	3 Months Ended				6 Months Ended
Pay vs Performance Disclosure - USD ($)	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (3,470,052)	$ (2,810,091)	$ (3,259,097)	$ (4,379,890)	$ (6,280,143)	$ (7,638,987)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2024	Aug. 09, 2024
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-39069
Entity Registrant Name	Aprea Therapeutics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	84-2246769
Entity Address, Address Line One	3805 Old Easton Road
Entity Address, City or Town	Doylestown
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	18902
City Area Code	617
Local Phone Number	463-9385
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	APRE
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,431,903
Entity Central Index Key	0001781983
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity - USD ($)	Series A Convertible Preferred Stock Preferred Stock	Series A Convertible Preferred Stock	Common Stock At Market Offering [Member]	Common Stock	Additional Paid-in capital At Market Offering [Member]	Additional Paid-in capital	Accumulated other comprehensive loss	Accumulated deficit	At Market Offering [Member]	Total
Temporary equity, beginning balance (in shares) at Dec. 31, 2022	56,227
Temporary equity, beginning balance at Dec. 31, 2022	$ 1,311,063
Temporary equity, ending balance (in shares) at Mar. 31, 2023	56,227
Temporary equity, ending balance at Mar. 31, 2023	$ 1,311,063
Equity, beginning balance at Dec. 31, 2022				$ 2,655		$ 330,060,836	$ (10,623,408)	$ (293,796,405)		$ 25,643,678
Equity, beginning balance (in shares) at Dec. 31, 2022				2,655,269
Increase (Decrease) in Stockholders' Equity
Issuance of common stock, net			$ 26	$ 1,050	$ 268,099	4,870,815			$ 268,125	4,871,865
Issuance of common stock, net (in shares)			26,302	1,050,000
Stock-based compensation						16,244				16,244
Foreign currency translation							61,956			61,956
Net Income (Loss)								(4,379,890)		(4,379,890)
Equity, ending balance at Mar. 31, 2023				$ 3,731		335,215,994	(10,561,452)	(298,176,295)		26,481,978
Equity, ending balance (in shares) at Mar. 31, 2023				3,731,571
Temporary equity, beginning balance (in shares) at Dec. 31, 2022	56,227
Temporary equity, beginning balance at Dec. 31, 2022	$ 1,311,063
Temporary equity, ending balance (in shares) at Jun. 30, 2023	56,227
Temporary equity, ending balance at Jun. 30, 2023	$ 1,311,063
Equity, beginning balance at Dec. 31, 2022				$ 2,655		330,060,836	(10,623,408)	(293,796,405)		25,643,678
Equity, beginning balance (in shares) at Dec. 31, 2022				2,655,269
Increase (Decrease) in Stockholders' Equity
Issuance of common stock, net (in shares)									26,302
Foreign currency translation										(11,464)
Net Income (Loss)										(7,638,987)
Equity, ending balance at Jun. 30, 2023				$ 3,731		335,485,317	(10,634,872)	(301,435,392)		23,418,784
Equity, ending balance (in shares) at Jun. 30, 2023				3,731,571
Temporary equity, beginning balance (in shares) at Mar. 31, 2023	56,227
Temporary equity, beginning balance at Mar. 31, 2023	$ 1,311,063
Temporary equity, ending balance (in shares) at Jun. 30, 2023	56,227
Temporary equity, ending balance at Jun. 30, 2023	$ 1,311,063
Equity, beginning balance at Mar. 31, 2023				$ 3,731		335,215,994	(10,561,452)	(298,176,295)		26,481,978
Equity, beginning balance (in shares) at Mar. 31, 2023				3,731,571
Increase (Decrease) in Stockholders' Equity
Stock-based compensation						269,323				269,323
Foreign currency translation							(73,420)			(73,420)
Net Income (Loss)								(3,259,097)		(3,259,097)
Equity, ending balance at Jun. 30, 2023				$ 3,731		335,485,317	(10,634,872)	(301,435,392)		23,418,784
Equity, ending balance (in shares) at Jun. 30, 2023				3,731,571
Temporary equity, beginning balance (in shares) at Dec. 31, 2023	56,227	56,227
Temporary equity, beginning balance at Dec. 31, 2023	$ 1,311,063	$ 1,311,063
Temporary equity, ending balance (in shares) at Mar. 31, 2024	56,227
Temporary equity, ending balance at Mar. 31, 2024	$ 1,311,063
Equity, beginning balance at Dec. 31, 2023				$ 3,736		335,644,204	(10,611,273)	(308,083,161)		16,953,506
Equity, beginning balance (in shares) at Dec. 31, 2023				3,736,673
Increase (Decrease) in Stockholders' Equity
Issuance of common stock, net				$ 1,688		14,708,017				14,709,705
Issuance of common stock, net (in shares)				1,687,712
Vesting of restricted stock units				$ 6		(6)
Vesting of restricted stock units (in shares)				5,830
Stock-based compensation						85,830				85,830
Foreign currency translation							(15,083)			(15,083)
Net Income (Loss)								(2,810,091)		(2,810,091)
Equity, ending balance at Mar. 31, 2024				$ 5,430		350,438,045	(10,626,356)	(310,893,252)		28,923,867
Equity, ending balance (in shares) at Mar. 31, 2024				5,430,215
Temporary equity, beginning balance (in shares) at Dec. 31, 2023	56,227	56,227
Temporary equity, beginning balance at Dec. 31, 2023	$ 1,311,063	$ 1,311,063
Temporary equity, ending balance (in shares) at Jun. 30, 2024	56,227	56,227
Temporary equity, ending balance at Jun. 30, 2024	$ 1,311,063	$ 1,311,063
Equity, beginning balance at Dec. 31, 2023				$ 3,736		335,644,204	(10,611,273)	(308,083,161)		16,953,506
Equity, beginning balance (in shares) at Dec. 31, 2023				3,736,673
Increase (Decrease) in Stockholders' Equity
Foreign currency translation										(17,031)
Net Income (Loss)										(6,280,143)
Equity, ending balance at Jun. 30, 2024				$ 5,430		350,545,473	(10,628,304)	(314,363,304)		25,559,295
Equity, ending balance (in shares) at Jun. 30, 2024				5,430,215
Temporary equity, beginning balance (in shares) at Mar. 31, 2024	56,227
Temporary equity, beginning balance at Mar. 31, 2024	$ 1,311,063
Temporary equity, ending balance (in shares) at Jun. 30, 2024	56,227	56,227
Temporary equity, ending balance at Jun. 30, 2024	$ 1,311,063	$ 1,311,063
Equity, beginning balance at Mar. 31, 2024				$ 5,430		350,438,045	(10,626,356)	(310,893,252)		28,923,867
Equity, beginning balance (in shares) at Mar. 31, 2024				5,430,215
Increase (Decrease) in Stockholders' Equity
Issuance costs						(21,060)				(21,060)
Stock-based compensation						128,488				128,488
Foreign currency translation							(1,948)			(1,948)
Net Income (Loss)								(3,470,052)		(3,470,052)
Equity, ending balance at Jun. 30, 2024				$ 5,430		$ 350,545,473	$ (10,628,304)	$ (314,363,304)		$ 25,559,295
Equity, ending balance (in shares) at Jun. 30, 2024				5,430,215

Commitments and contingencies (Details)	6 Months Ended
Commitments and contingencies (Details)	Jun. 30, 2024 USD ($)
Commitments and contingencies.
Provision for contingent losses	$ 0

Nature of business and basis of presentation (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Nature of business and basis of presentation
Cash balance	$ 28,694,694	$ 21,606,820	$ 27,685,131

Summary of significant accounting policies (Policies)

6 Months Ended

Jun. 30, 2024

Summary of significant accounting policies

Principles of consolidation

Principles of consolidation—The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Aprea Therapeutics AB, which was incorporated in May 2009, Aprea US, Inc., which was incorporated in June 2016 and ATR Pharmaceuticals LLC which was incorporated in May 2022. Management has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations. All intercompany transactions and balances have been eliminated.

Unaudited interim consolidated financial statements

Unaudited interim consolidated financial statements—The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company in accordance with U.S. GAAP for interim information and pursuant to the rules and regulations of the SEC for reporting on Form 10-Q. Accordingly, certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed interim financial statements

should be read in conjunction with the audited financial statements and related notes included in the Company’s annual report on Form 10-K for the year ended December 31, 2023 filed with the SEC.

The unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements, and in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods have been made. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the full fiscal year or any future period.

Use of estimates

Use of estimates—The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions, are used for, but not limited to, include stock-based compensation and accounting for research and development costs.

Foreign currency and currency translation

Foreign currency and currency translation—The functional currency for Aprea Therapeutics AB is the Swedish Krona. Assets and liabilities of Aprea Therapeutics AB are translated into United States dollars at the exchange rate in effect on the balance sheet date. Operating expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the consolidated statements of stockholders’ equity as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income, net in the condensed consolidated statements of operations and comprehensive loss as incurred.

Cash and cash equivalents and restricted cash

Cash and cash equivalents— The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.

Restricted cash— The Company has restricted cash of approximately $41,000 that is securing the Company’s credit card program.

Fair value of financial instruments

Fair value of financial instruments—The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (“ASC 820”), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable:

●	Level 1 inputs: Quoted prices in active markets for identical assets or liabilities.

●	Level 2 inputs: Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.

●	Level 3 inputs: Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in

determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The Company’s financial instruments consist of cash, cash equivalents, restricted cash, accounts payable and accrued expenses. The carrying amount of accounts payable and accrued expenses is considered a reasonable estimate of fair value due to the short-term maturity.

Series A Convertible Preferred Stock

Series A Convertible Preferred Stock—The Company classifies the Series A Preferred Stock as temporary equity outside of stockholders’ equity on the accompanying condensed consolidated balance sheets due to certain events that are not within the Company's control. The Series A Preferred Stock was recorded at fair value upon the acquisition of Atrin in May 2022.

Accounting for leases

Accounting for leases—At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company’s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding right of use assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.

The Company has elected not to separate lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as right of use (ROU) lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis. The Company has also elected the short-term lease exemption for all leases with an original term of less than 12 months.

Research and development costs

Research and development costs—Research and development costs are charged to expense as incurred. Research and development expenses incurred in performing research and development activities, include salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development. Deposits made by the Company with certain service providers that are to be applied to future payments due under the service agreements or returned to the Company if not utilized are recorded in the consolidated balance sheets.

Revenue recognition

Revenue recognition— The Company’s revenue is primarily generated through grants from government and non-government organizations. Grant revenue is recognized during the period that the reimbursable research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. Grant revenue received in advance is recorded as deferred grant revenue and recognized as revenue once the conditions for revenue recognition are met. Associated expenses are recognized when incurred as research and development expenses. The Company concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606, Revenue from Contracts with Customers, as the organizations providing the grants do not meet the definition of a customer.

Stock-based compensation

Stock-based compensation—The Company measures stock options and other stock-based awards granted to employees and directors based on their fair value on the date of the grant and recognize compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company applies the straight-line method of expense recognition to all awards with only service based vesting conditions.

For stock-based awards granted to non-employees, compensation expense is recognized over the period during which services are rendered by such non-employees until completed in accordance with ASC 718.

The Company estimates the fair value of each stock option grant on the date of grant using the Black Scholes option pricing model, which uses as inputs the fair value of the Company’s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. The Company elects to account for forfeitures when they occur.

The Company also awards restricted stock units (“RSUs”) to employees and directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.

Net loss per share

Net loss per share—The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same.

The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):


	Six months ended June 30,
	2024	2023
Convertible preferred stock (as converted)	28,112	28,112
Options to purchase common stock	734,131	558,141
Warrants to purchase common stock	2,194,788	—
Unvested restricted stock units	41,130	25,972
Total shares of common stock equivalents	2,998,161	612,225

Recently issued accounting pronouncements

Recently issued accounting pronouncements—From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date.

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying financial statements.

Accrued expenses (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Accrued expenses
Professional fees	$ 209,372	$ 138,601
Compensation, severance and benefits	582,437	1,016,960
Research and development	1,240,751	856,575
Other	46,603	174,126
Total accrued expenses	$ 2,079,163	$ 2,186,262

Stockholders' equity (Details)			1 Months Ended	3 Months Ended		6 Months Ended
Stockholders' equity (Details)	Mar. 11, 2024 USD ($) $ / shares shares	Nov. 12, 2020 USD ($)	Feb. 28, 2023 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) Vote $ / shares shares	Jun. 30, 2023 USD ($) shares	Mar. 31, 2024 $ / shares shares	Jan. 26, 2024 USD ($)	Dec. 31, 2023 $ / shares shares
Common stock
Stock, shares authorized \| shares				440,000,000		440,000,000
Common stock, shares authorized \| shares				400,000,000		400,000,000		400,000,000		400,000,000
Common stock, par value (in dollars per share) \| $ / shares				$ 0.001		$ 0.001		$ 0.001		$ 0.001
Preferred stock, shares authorized \| shares				40,000,000		40,000,000
Preferred stock, par value (in dollars per share) \| $ / shares				$ 0.001		$ 0.001
Common stock issuable upon conversion (in shares) \| shares				28,112		28,112
Number of voting rights per common share \| Vote						1
Stock based compensation expense				$ 128,488	$ 269,323	$ 214,318	$ 285,567
Shelf Registration Statement
Proceeds from issuance of common stock						15,999,598	5,788,918
Common stock issuance costs						1,310,953	$ 648,928
March 2024 Private Placement
Warrant exercises						$ 0
Series A Convertible Preferred Stock
Common stock
Convertible preferred stock, shares outstanding \| shares				56,227		56,227				56,227
March 2024 Private Placement \| Purchasers \| Securities purchase agreement
Shelf Registration Statement
Shares issued \| shares	1,687,712
Common stock issuance costs	$ 1,300,000
March 2024 Private Placement
Offering price per share \| $ / shares	$ 7.29
Common stock with an exercise price \| $ / shares	$ 0.001
Percentage of outstanding shares	4.99%
Proceeds from sale of common stock in a private placement	$ 16,000,000.0
Expected gross proceeds from potential future warrants cash exercise	$ 18,000,000.0
March 2024 Private Placement \| Purchasers \| Securities purchase agreement \| At the election of holder
March 2024 Private Placement
Percentage of outstanding shares	9.99%
March 2024 Private Placement \| Purchasers \| Securities purchase agreement \| Pre-funded Warrants
March 2024 Private Placement
Offering price per share \| $ / shares	$ 7.289
Warrants to purchase of shares \| shares	507,076
March 2024 Private Placement \| Purchasers \| Securities purchase agreement \| Tranche A Warrants (Pre-funded Warrants Exercise Price 7.29 Per Share)
March 2024 Private Placement
Warrants to purchase of shares \| shares	1,097,394
Common stock with an exercise price \| $ / shares	$ 7.29
Stock issuance anniversary period	3 years
Number of days after announcement of Phase 2 dose for ATRN-119	30 days
Volume weighted average price \| $ / shares	$ 14.58
Number of consecutive trading days	30 days
March 2024 Private Placement \| Purchasers \| Securities purchase agreement \| Tranche B Warrants (Pre-funded Warrants Exercise Price 9.1125 Per Share)
March 2024 Private Placement
Common stock with an exercise price \| $ / shares	$ 9.1125
Stock issuance anniversary period	5 years
Number of days after announcement of Phase 2 dose for ATRN-119	30 days
Volume weighted average price \| $ / shares	$ 18.225
2020 Shelf Registration Statement
Shelf Registration Statement
Maximum amount to be issued under universal shelf registration statement		$ 350,000,000.0
2020 Shelf Registration Statement \| Common Stock
Shelf Registration Statement
Shares issued \| shares			1,050,000
Issue price per share \| $ / shares			$ 5.25
Proceeds from issuance of common stock			$ 4,900,000
Common stock issuance costs			$ 600,000
ATM offering
Common stock
Commission payable as a percentage of gross proceeds from sale of common stock under ATM offering		3.00%
Shelf Registration Statement
Maximum amount to be issued under at-the-market offering program		$ 14,744,728
Shares issued \| shares							26,302
Proceeds from issuance of common shares							$ 300,000
Common stock issuance costs							$ 8,000
2024 Shelf Registration Statement
Shelf Registration Statement
Maximum amount to be issued under universal shelf registration statement									$ 150,000,000
Maximum amount to be issued under at-the-market offering program									1,000,000
Maximum amount to be issued under at-the-market offering program, supplement									2,000,000
2024 ATM offering \| HCW
Shelf Registration Statement
Maximum amount to be issued under at-the-market offering program									$ 2,000,000

Commitments and contingencies

6 Months Ended

Jun. 30, 2024

Commitments and contingencies.

Commitments and contingencies

7. Commitments and contingencies

The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. As of June 30, 2024, the Company has not recorded a provision for any contingent losses.

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	5,430,215	3,736,673
Common stock, shares outstanding	5,430,215	3,736,673
Series A Convertible Preferred Stock
Convertible preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	40,000,000	40,000,000
Convertible preferred stock, shares issued	56,227	56,227
Convertible preferred stock, shares outstanding	56,227	56,227

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss			$ (6,280,143)	$ (7,638,987)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			11,461	634
Stockbased compensation			214,318	285,567
Foreign currency (gain) loss	$ 5,502	$ (56,363)	(50,674)	(42,566)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets			(223,296)	410,246
Accounts payable			(703,473)	289,605
Accrued expenses			(67,470)	499,516
Deferred grant revenue			(478,235)
Net cash used in operating activities			(7,577,512)	(6,195,985)
Cash flows from investing activities:
Purchases of property and equipment			(15,478)
Net cash used in investing activities			(15,478)
Cash flows from financing activities:
Proceeds from issuance of common stock			15,999,598	5,788,918
Common stock issuance costs			(1,310,953)	(648,928)
Net cash provided by financing activities			14,688,645	5,139,990
Change in cash and cash equivalents and restricted cash			7,095,655	(1,055,995)
Effect of exchange rate changes on cash, cash equivalents and restricted cash			(7,238)	(5,341)
Cash, cash equivalents and restricted cash-beginning of year			21,647,537	28,786,647
Cash, cash equivalents and restricted cash-end of period	28,735,954	27,725,311	28,735,954	27,725,311
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	28,694,694	27,685,131	28,694,694	27,685,131
Restricted cash	41,260	40,180	41,260	40,180
Total cash, cash equivalents and restricted cash	$ 28,735,954	$ 27,725,311	$ 28,735,954	$ 27,725,311

Stockholders' equity

6 Months Ended

Jun. 30, 2024

Stockholders' equity

Stockholders' equity

5. Stockholders’ equity

The total number of shares of all classes of capital stock that the Company is authorized to issue is 440,000,000 shares, consisting of 400,000,000 shares of common stock, par value $0.001 per share and 40,000,000 shares of preferred stock, par value $0.001 per share.

Series A Preferred Stock

As of June 30, 2024, a total of 56,227 shares of Series A Preferred Stock remained outstanding, which are convertible into 28,112 shares of common stock.

Common Stock

The holders of common stock are entitled to one vote for each share of common stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company, the holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution, if any.

Shelf Registration Statement

On November 12, 2020, the Company filed a universal shelf registration statement with the SEC for the issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate of $350.0 million (the “2020 Shelf Registration Statement”). On November 30, 2020, the 2020 Shelf Registration Statement was declared effective by the SEC and on November 30, 2023, the 2020 Shelf Registration Statement expired. The 2020 Shelf Registration Statement included an at-the-market offering program with SVB Leerink LLC (the “SVB ATM Program”) and the Company filed a Prospectus Supplement dated September 2, 2022, for the sale of up to $14,744,728 of shares of the Company’s common stock pursuant to its ATM offering program. The Company agreed to pay a commission of 3% of the gross proceeds of any common stock sold in connection with the SVB ATM Program. During the six months ended June 30, 2023, the Company issued and sold 26,302 shares of common stock under the ATM offering program resulting in net proceeds to the Company of approximately $0.3 million after deducting approximately $8,000 in issuance costs. The SVB ATM Program has terminated and is no longer effective.

In February 2023, the Company issued and sold 1,050,000 shares of common stock at a public offering price of $5.25 per share pursuant to the 2020 Shelf Registration Statement resulting in net proceeds to the Company of approximately $4.9 million, after deducting underwriting discounts and offering expenses of approximately $0.6 million.

On January 26, 2024, the Company filed a new shelf registration statement (the “2024 Shelf Registration Statement”) with the SEC for issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate of $150 million, including a prospectus for the sale of $1 million of shares of our common stock under the ATM Agreement, as defined below, which was declared effective on February 2, 2024. The Company subsequently filed a prospectus supplement to the 2024 Shelf Registration Statement for the sale of up to $2 million of shares of common stock pursuant to the ATM Agreement. On January 26, 2024, the Company entered into an At the Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“HCW”). Pursuant to the ATM Agreement and the prospectus supplement filed in connection therewith, the Company was able, from time to time, in its sole discretion, to issue and sell through HCW, acting as sales agent and/or principal, up to $2 million of shares of common stock. The Company did not make any sales under the ATM Agreement and in March 2024, the Company terminated the ATM Agreement with HCW.

March 2024 Private Placement

On March 11, 2024, the Company entered into a securities purchase agreement with certain purchasers (the “Purchasers”) pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement offering exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, and the Purchasers agreed to purchase from the Company (i) 1,687,712 shares of the Company’s common stock at a purchase price of $7.29 per share (the “Shares”), (ii) pre-funded common stock purchase warrants at a purchase price of $7.289 to purchase an aggregate of up to 507,076 shares of the Company’s common stock at an exercise price of $0.001 per share (the “Pre-Funded Shares”), (iii) tranche A common stock purchase warrants to purchase up to 1,097,394 shares of the Company’s common stock at an exercise price of $7.29 per share (the “Tranche A Warrants”), and (iv) tranche B common stock purchase warrants to purchase up to 1,097,394 shares of the Company’s common stock at an exercise price of $9.1125 per share (the “Tranche B Warrants”). The Tranche A Warrants will be exercisable until the earlier of (i) the three-year anniversary of issuance and (ii) 30 days after the Company announces the recommended Phase 2 dose for ATRN-119, and, following such announcement, the daily volume weighted average price of the Company’s common stock equals or exceeds $14.58 for 30 consecutive trading days. The Tranche B Warrants will be exercisable until the earlier of (i) the five-year anniversary of issuance and (ii) 30 days after the Company announces the recommended Phase 2 dose for APR-1051 and, following such announcement, the daily volume weighted average price of the Company’s common stock equals or exceeds $18.225 for 30 consecutive trading days. To the extent that the exercise of a Tranche A Warrant or Tranche B Warrant would result in the holder beneficially owning greater than 4.99% (or, at the election of the holder, greater than 9.99%) of the Company’s outstanding common stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate upfront gross proceeds from the issuance of common stock and pre-funded common stock purchase warrants totaled approximately $16.0 million, before deducting placement agent fees and offering costs of approximately $1.3 million. The gross proceeds from potential future warrant cash exercises are expected to be up to approximately $18.0 million, before deducting placement agent fees. In April 2024, we registered on Form S-3 the resale of the Shares, the Pre-Funded Shares and the shares underlying the Tranche A Warrants and Tranche B Warrants.

The Company evaluated the terms of the warrants issued and determined that they should be classified as equity instruments within additional paid-in capital. As of June 30, 2024, none of the pre-funded warrants, Tranche A Warrants or Tranche B Warrants have been exercised.

Stock-Based Compensation Expense

The Company recorded stock-based compensation expense of $128,488 and $269,323 for the three months ended June 30, 2024 and 2023, respectively. The Company recorded stock-based compensation expense of $214,318 and $285,567 for the six months ended June 30, 2024 and 2023, respectively.

Income taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Income taxes - Narrative (Details) - USD ($) $ in Millions	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Income taxes
Income tax expense	$ 0.0	$ 0.0	$ 0.0	$ 0.0
Uncertain tax positions	$ 0.1		$ 0.1		$ 0.1

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Insider Trading Arrangements	6 Months Ended
Insider Trading Arrangements	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of significant accounting policies - Potentially dilutive securities (Details) - shares	3 Months Ended	6 Months Ended
	Mar. 31, 2023	Jun. 30, 2024
Potentially dilutive securities
Total shares of common stock equivalents	612,225	2,998,161
Convertible preferred stock (as converted)
Potentially dilutive securities
Total shares of common stock equivalents	28,112	28,112
Employee Stock Option
Potentially dilutive securities
Total shares of common stock equivalents	558,141	734,131
Warrants to purchase common stock
Potentially dilutive securities
Total shares of common stock equivalents		2,194,788
Unvested restricted stock units
Potentially dilutive securities
Total shares of common stock equivalents	25,972	41,130

Summary of significant accounting policies

6 Months Ended

Jun. 30, 2024

Summary of significant accounting policies

Summary of significant accounting policies

2. Summary of significant accounting policies

The Company's complete listing of significant accounting policies are described in Note 2 to the Company's audited consolidated financial statements as of December 31, 2023 included in its annual report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”).

should be read in conjunction with the audited financial statements and related notes included in the Company’s annual report on Form 10-K for the year ended December 31, 2023 filed with the SEC.

Cash and cash equivalents— The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.

Restricted cash— The Company has restricted cash of approximately $41,000 that is securing the Company’s credit card program.

●	Level 1 inputs: Quoted prices in active markets for identical assets or liabilities.

●	Level 2 inputs: Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.

●	Level 3 inputs: Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.


	Six months ended June 30,
	2024	2023
Convertible preferred stock (as converted)	28,112	28,112
Options to purchase common stock	734,131	558,141
Warrants to purchase common stock	2,194,788	—
Unvested restricted stock units	41,130	25,972
Total shares of common stock equivalents	2,998,161	612,225

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying financial statements.

Summary of significant accounting policies (Tables)

6 Months Ended

Jun. 30, 2024

Summary of significant accounting policies

Schedule of potentially dilutive securities excluded from calculation of diluted net loss per share


	Six months ended June 30,
	2024	2023
Convertible preferred stock (as converted)	28,112	28,112
Options to purchase common stock	734,131	558,141
Warrants to purchase common stock	2,194,788	—
Unvested restricted stock units	41,130	25,972
Total shares of common stock equivalents	2,998,161	612,225

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Condensed Consolidated Statements of Operations and Comprehensive Loss
Grant revenue	$ 561,574	$ 249,688	$ 942,143	$ 249,688
Operating expenses:
Research and development	2,557,679	2,202,657	4,158,052	3,459,199
General and administrative	1,850,819	1,698,712	3,780,685	5,064,673
Total operating expenses	4,408,498	3,901,369	7,938,737	8,523,872
Loss from operations	(3,846,924)	(3,651,681)	(6,996,594)	(8,274,184)
Other income (expense):
Interest income, net	382,374	336,221	665,777	592,631
Foreign currency (loss) gain	(5,502)	56,363	50,674	42,566
Total other income	376,872	392,584	716,451	635,197
Net loss	(3,470,052)	(3,259,097)	(6,280,143)	(7,638,987)
Other comprehensive (loss):
Foreign currency translation	(1,948)	(73,420)	(17,031)	(11,464)
Total comprehensive loss	$ (3,472,000)	$ (3,332,517)	$ (6,297,174)	$ (7,650,451)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.58)	$ (0.87)	$ (1.24)	$ (2.18)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.58)	$ (0.87)	$ (1.24)	$ (2.18)
Weighted-average common shares outstanding, basic (in shares)	5,937,291	3,731,571	5,067,809	3,497,329
Weighted-average common shares outstanding, diluted (in shares)	5,937,291	3,731,571	5,067,809	3,497,329